SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Elisa Leo, Manuela Mancini, Fausto Castagnetti, Gabriele Gugliotta, Maria Alessandra Santucci, Giovanni Martinelli, DNA Methyltransferase 1 Drives Transcriptional Down-Modulation of β Catenin Antagonist Chibby1 Associated With the BCR-ABL1 Gene of Chronic Myeloid Leukemia, Journal of Cellular Biochemistry, 2015, 116, 4
  2. 2
    S. Saußele, Richard T. Silver, Management of chronic myeloid leukemia in blast crisis, Annals of Hematology, 2015, 94, S2, 159

    CrossRef

  3. 3
    Stephanie M. Tortorella, Andrew Hung, Tom C. Karagiannis, The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia, Antioxidants & Redox Signaling, 2015, 22, 16, 1425

    CrossRef

  4. 4
    Shyamala C. Navada, Juliane Steinmann, Michael Lübbert, Lewis R. Silverman, Clinical development of demethylating agents in hematology, Journal of Clinical Investigation, 2014, 124, 1, 40

    CrossRef

  5. 5
    Binghao Li, Zhaoming Ye, Epigenetic alterations in osteosarcoma: promising targets, Molecular Biology Reports, 2014, 41, 5, 3303

    CrossRef

  6. 6
    Paolo Strati, Hagop Kantarjian, Deborah Thomas, Susan O'Brien, Sergej Konoplev, Jeffrey L. Jorgensen, Raja Luthra, Lynne Abruzzo, Elias Jabbour, Alfonso Quintas-Cardama, Gautam Borthakur, Stefan Faderl, Farhad Ravandi, Jorge Cortes, HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia, Cancer, 2014, 120, 3
  7. 7
    Selcen Celik, Dilara Akcora, Tulin Ozkan, Nuray Varol, Sena Aydos, Asuman Sunguroglu, Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients, Oncology Letters, 2014,

    CrossRef

  8. 8
    Elias J. Jabbour, Timothy P. Hughes, Jorge E. Cortés, Hagop M. Kantarjian, Andreas Hochhaus, Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia, Leukemia & Lymphoma, 2014, 55, 7, 1451

    CrossRef

  9. 9
    David Ghez, Jean-Baptiste Micol, Florence Pasquier, Nathalie Auger, Véronique Saada, Marc Spentchian, Jean-Christophe Ianotto, Jean-Henri Bourhis, Anelyse Bennaceur-Griscelli, Christine Terré, Sylvie Castaigne, Sophie Rigaudeau, Philippe Rousselot, Stéphane de Botton, Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis, European Journal of Cancer, 2013, 49, 17, 3666

    CrossRef

  10. 10
    Elias J. Jabbour, Jorge E. Cortes, Hagop M. Kantarjian, Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options, Clinical Lymphoma Myeloma and Leukemia, 2013, 13, 5, 515

    CrossRef

  11. 11
    Katerina Machova Polakova, Jitka Koblihova, Tomas Stopka, Role of Epigenetics in Chronic Myeloid Leukemia, Current Hematologic Malignancy Reports, 2013, 8, 1, 28

    CrossRef

  12. 12
    Qin Chen, Jiang Lin, Jun Qian, Zhao-Qun Deng, Wei Qian, Jing Yang, Yun Li, Xing-Xing Chen, Yu-Juan Ma, Ji-Chun Ma, Qing Liu, The Methylation Status of theDDX43Promoter in Chinese Patients with Chronic Myeloid Leukemia, Genetic Testing and Molecular Biomarkers, 2013, 17, 6, 508

    CrossRef

  13. 13
    Madhava Baikaidi, Stephen S. Chung, Martin S. Tallman, Lloyd E. Damon, Alison R. Walker, Guido Marcucci, Abdalla M. Sholi, Gloria J. Morris, A 75-Year-Old Woman With Thoracic Spinal Cord Compression and Chloroma (granulocytic sarcoma), Seminars in Oncology, 2012, 39, 6, e37

    CrossRef

  14. 14
    Melanie R. Hassler, Aleksandra Klisaroska, Karoline Kollmann, Irene Steiner, Martin Bilban, Ana-Iris Schiefer, Veronika Sexl, Gerda Egger, Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma, Biochimie, 2012, 94, 11, 2297

    CrossRef

  15. 15
    John R Bracht, David H Perlman, Laura F Landweber, Cytosine methylation and hydroxymethylation mark DNA for elimination in Oxytricha trifallax, Genome Biology, 2012, 13, 10, R99

    CrossRef

  16. 16
    Eduardo Cervera, Myrna Candelaria, Omar López-Navarro, Juan Labardini, Aurora Gonzalez-Fierro, Lucia Taja-Chayeb, Jorge Cortes, Daniela Gordillo-Bastidas, Alfonso Dueñas-González, Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia, Clinical Lymphoma Myeloma and Leukemia, 2012, 12, 3, 207

    CrossRef

  17. 17
    Bastian Scholz, Rolf Marschalek, Epigenetics and blood disorders, British Journal of Haematology, 2012, 158, 3
  18. 18
    Kyu-Tae Kim, David Mossman, Donald Small, Rodney J. Scott, Gene Expression Profiling of Human Myeloid Leukemic MV4-11 Cells Treated with 5-Aza-2’-deoxycytidine, Journal of Cancer Therapy, 2012, 03, 03, 177

    CrossRef

  19. 19
    R. Hehlmann, How I treat CML blast crisis, Blood, 2012, 120, 4, 737

    CrossRef

  20. 20
    Maria Florencia Tanaka, Hagop Kantarjian, Jorge Cortes, Maro Ohanian, Elias Jabbour, Treatment options for chronic myeloid leukemia, Expert Opinion on Pharmacotherapy, 2012, 13, 6, 815

    CrossRef

  21. 21
    Kelsey C. Bertrand, Stephen C. Mack, Paul A. Northcott, Livia Garzia, Adrian Dubuc, Stefan M. Pfister, James T. Rutka, William A. Weiss, Michael D. Taylor, PCDH10 is a candidate tumour suppressor gene in medulloblastoma, Child's Nervous System, 2011, 27, 8, 1243

    CrossRef

  22. 22
    D Bixby, M Talpaz, Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia, Leukemia, 2011, 25, 1, 7

    CrossRef

  23. 23
    Giovanni Luca Gravina, Francesco Marampon, Mario Di Staso, Pierluigi Bonfili, Alessandro Vitturini, Emmanuele A. Jannini, Richard G. Pestell, Vincenzo Tombolini, Claudio Festuccia, 5-azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors, The Prostate, 2010, 70, 11
  24. 24
    Janice P. Dutcher, Evelyn L. Morris, Bruce Gaynor, Elisabeth Paietta, Peter H. Wiernik, A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia, Medical Oncology, 2010, 27, 3, 728

    CrossRef

  25. You have free access to this content25
    Caterina Musolino, Emanuela Sant’Antonio, Giuseppa Penna, Andrea Alonci, Sabina Russo, Angela Granata, Alessandro Allegra, Epigenetic therapy in myelodysplastic syndromes, European Journal of Haematology, 2010, 84, 6
  26. 26
    Rani E. George, Jill M. Lahti, Peter C. Adamson, Kejin Zhu, David Finkelstein, A. Mark Ingle, Joel M. Reid, Mark Krailo, Donna Neuberg, Susan M. Blaney, Lisa Diller, Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study, Pediatric Blood & Cancer, 2010, 55, 4
  27. 27
    E. Schafer, R. Irizarry, S. Negi, E. McIntyre, D. Small, M. E. Figueroa, A. Melnick, P. Brown, Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting, Blood, 2010, 115, 23, 4798

    CrossRef

  28. 28
    Xiaojing Yang, Fides Lay, Han Han, Peter A. Jones, Targeting DNA methylation for epigenetic therapy, Trends in Pharmacological Sciences, 2010, 31, 11, 536

    CrossRef

  29. 29
    Lisa A Cowan, Sundeep Talwar, Allen S Yang, Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors, Epigenomics, 2010, 2, 1, 71

    CrossRef

  30. 30
    Jun Qian, Ya-li Wang, Jiang Lin, Dong-ming Yao, Wen-rong Xu, Chao-yang Wu, Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia, European Journal of Haematology, 2009, 82, 2
  31. 31
    Edurne San José-Eneriz, Xabier Agirre, Antonio Jiménez-Velasco, Lucia Cordeu, Vanesa Martín, Victor Arqueros, Leire Gárate, Vicente Fresquet, Francisco Cervantes, José A. Martínez-Climent, Anabel Heiniger, Antonio Torres, Felipe Prósper, Jose Roman-Gomez, Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia, European Journal of Cancer, 2009, 45, 10, 1877

    CrossRef

  32. 32
    Alessandro M. Vannucchi, Paola Guglielmelli, Alessandro Rambaldi, Costanza Bogani, Tiziano Barbui, Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives, Journal of Cellular and Molecular Medicine, 2009, 13, 8a
  33. 33
    Hanna Piotrowska, Pawel P. Jagodzinski, Glucocorticoid Receptor α and β Variant Expression Is Associated with ASF/SF2 Splicing Factor Upregulation in HT-29 Colon Cancer and MCF-7 Breast Carcinoma Cells, Archives of Medical Research, 2009, 40, 3, 156

    CrossRef

  34. 34
    Philippe Aftimos, Fady Nasr, Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: Case report and review of the literature, Leukemia Research, 2009, 33, 11, e178

    CrossRef

  35. 35
    Mike G. Martin, John F. Dipersio, Geoffrey L. Uy, Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors, Leukemia & Lymphoma, 2009, 50, 1, 14

    CrossRef

  36. 36
    Antigoni Avramouli, Stefanos Tsochas, Eudokia Mandala, Eirini Katodritou, Maria Ioannou, Konstantinos Ritis, Matthaios Speletas, Methylation status of RASSF1A in patients with chronic myeloid leukemia, Leukemia Research, 2009, 33, 8, 1130

    CrossRef

  37. 37
    Elias Jabbour, Jorge Cortes, Hagop Kantarjian, Treatment selection after imatinib resistance in chronic myeloid leukemia, Targeted Oncology, 2009, 4, 1, 3

    CrossRef

  38. 38
    E. Miller-Kasprzak, P.P. Jagodziński, 5-Aza-2′-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells, Biomedicine & Pharmacotherapy, 2008, 62, 3, 158

    CrossRef

  39. 39
    Peter Valent, Michael Deininger, Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia, Leukemia & Lymphoma, 2008, 49, 4, 604

    CrossRef

  40. 40
    Guillermo Garcia-Manero, Demethylating agents in myeloid malignancies, Current Opinion in Oncology, 2008, 20, 6, 705

    CrossRef

  41. 41
    C. Kurkjian, S. Kummar, A.J. Murgo, DNA Methylation: Its Role in Cancer Development and Therapy, Current Problems in Cancer, 2008, 32, 5, 187

    CrossRef

  42. 42
    Elias Jabbour, Jean-Pierre Issa, Guillermo Garcia-Manero, Hagop Kantarjian, Evolution of decitabine development, Cancer, 2008, 112, 11
  43. 43
    A. Kozłowska, P.P. Jagodziński, Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine kinase expression in Hut-78 T-lymphoma cells, Biomedicine & Pharmacotherapy, 2008, 62, 10, 672

    CrossRef

  44. 44
    Current Awareness in Hematological Oncology, Hematological Oncology, 2007, 25, 4
  45. 45
    Elizabeth R. Plimack, Hagop M. Kantarjian, Jean-Pierre Issa, Decitabine and its role in the treatment of hematopoietic malignancies, Leukemia & Lymphoma, 2007, 48, 8, 1472

    CrossRef

  46. 46
    Mark Bishton, Melita Kenealy, Ricky Johnstone, Walid Rasheed, H Miles Prince, Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents, Expert Review of Anticancer Therapy, 2007, 7, 10, 1439

    CrossRef

  47. 47
    Hagop Kantarjian, Ayalew Tefferi, From the Guest Editors, The Cancer Journal, 2007, 13, 6, 355

    CrossRef

  48. 48
    Jane E. Kihslinger, Lucy A. Godley, The use of hypomethylating agents in the treatment of hematologic malignancies, Leukemia & Lymphoma, 2007, 48, 9, 1676

    CrossRef

  49. 49
    Devendra K. Hiwase, Timothy P. Hughes, Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia,